Company Profile
Cellectis Stock Price, News & Analysis
- Ticker:
- CLLS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- France
Stock performance
2.69 USD (-3.58%)
Close
Last updated: August 6, 2026
340M USD
Market cap
Why the stock is moving
The latest monitored company update is “Cellectis Reports Financial Results for the Second Quarter 2026.” The corresponding closing-price reaction is not yet available.
Company overview
Gene-Edited Allogeneic Cell Therapy
Cellectis develops off-the-shelf CAR T-cell therapies using TALEN gene editing and related genome-engineering technologies.
UCART Platform
The platform modifies healthy donor T cells to add tumor targeting and reduce immune incompatibility, enabling standardized inventory-based treatment.
BALLI-01
The pivotal Phase 2 BALLI-01 study evaluates a Cellectis allogeneic CAR T therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.
Partnered Programs
Cellectis retains economic and technology exposure to partnered products including cema-cel, originally developed as UCART19 and advanced by Allogene and Servier.
TALE Epigenetic Editing
Beyond DNA-cutting applications, Cellectis is developing TALE-based epigenetic editing to regulate gene activity without creating double-strand DNA breaks.
Future catalysts
The first interim analysis from the pivotal Phase 2 BALLI-01 study is expected in the fourth quarter of 2026.
Study accrual is expected to complete by year-end 2027, with an interim event-free survival analysis in mid-2027 and primary analysis in mid-2028.
Cellectis anticipates a BLA submission in 2028.
Recent news
- 01
Cellectis Reports Financial Results for the Second Quarter 2026
Source: Cellectis
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cellectis (CLLS)?
Cellectis (CLLS) most recently closed at 2.69 USD, a -3.58% move versus the previous session.
What is the market cap of Cellectis (CLLS)?
Cellectis currently has a market capitalization of 340M USD on BioPharmSignal.
What does Cellectis do?
Gene-Edited Allogeneic Cell Therapy Cellectis develops off-the-shelf CAR T-cell therapies using TALEN gene editing and related genome-engineering technologies. UCART Platform The platform modifies healthy donor T cells to add tumor targeting and reduce immune incompatibility, enabling standardized inventory-based treatment. BALLI-01 The pivotal Phase 2...
On which exchange is CLLS stock listed?
Cellectis (CLLS) is associated with NASDAQ, France, Biopharma.
What is BALLI-01?
The first interim analysis from the pivotal Phase 2 BALLI-01 study is expected in the fourth quarter of 2026.
Which conditions is Cellectis targeting with BALLI-01?
Cellectis is associated with genetic disease based on its company overview and current catalyst commentary.
How does Cellectis describe recent progress with BALLI-01?
The first interim analysis from the pivotal Phase 2 BALLI-01 study is expected in the fourth quarter of 2026.
What is Gene-Edited?
Gene-Edited Allogeneic Cell Therapy Cellectis develops off-the-shelf CAR T-cell therapies using TALEN gene editing and related genome-engineering technologies.